Return on Equity (ROE): 5.25%
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 5.25% is 54% below its 5-year average of 11.34%, near the low end of its 5-year range (3.83%–16.60%).
As of Saturday, June 27, 2026. 12.21% below its 12-month average of 5.98%.
TECH Return on Equity (ROE) Chart
Annual fiscal-year return on equity; no daily interpolation.
TECH Average Return on Equity (ROE) Chart
TECH Current vs Average Return on Equity (ROE) Chart
TECH Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
5.25%
RETURN ON EQUITY (ROE) AVG TTM
5.98%
RETURN ON EQUITY (ROE) AVG 3Y
10.62%
RETURN ON EQUITY (ROE) AVG 5Y
11.34%
RETURN ON EQUITY (ROE) AVG 10Y
10.97%
RETURN ON EQUITY (ROE) AVG 15Y
12.97%
RETURN ON EQUITY (ROE) AVG 20Y
15.12%
CURRENT VS TTM AVG
-12.21%
CURRENT VS 3Y AVG
-50.54%
CURRENT VS 5Y AVG
-53.70%
CURRENT VS 10Y AVG
-52.13%
CURRENT VS 15Y AVG
-59.53%
CURRENT VS 20Y AVG
-65.28%
TECH Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Techne Corporation (TECH) | $11.12B | 5.25% | 5.98% | 10.62% | 11.34% |
| Insulet Corp. (PODD)vs › | $10.96B | 23.25% | 25.41% | 19.99% | 14.02% |
| Baxter International Inc. (BAX)vs › | $11.38B | -18.17% | -12.46% | -8.76% | -1.37% |
| Molina Healthcare, Inc. (MOH)vs › | $11.79B | 4.61% | 18.91% | 22.60% | 24.60% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -87.68% | -49.03% | -18.16% | -9.00% |
| Charles River Laboratories International, Inc. (CRL)vs › | $10.20B | -6.28% | -2.13% | 6.32% | 9.65% |
| Tempus AI, Inc. (TEM)vs › | $9.80B | -72.74% | -651.33% | -315.37% | -198.08% |
| Henry Schein, Inc. (HSIC)vs › | $9.68B | 12.09% | 11.88% | 12.69% | 13.50% |
| Revvity, Inc. (RVTY)vs › | $12.61B | 3.35% | 3.59% | 3.35% | 7.68% |
| Align Technology, Inc. (ALGN)vs › | $12.78B | 10.36% | 10.54% | 10.84% | 19.93% |
Return Analysis
ROE
5.3%
ROA
4.3%
Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The return on equity (ROE) for TECH stock is 5.25%.
- Is Bio-Techne Corporation's return on equity (ROE) high or low?
- The return on equity (ROE) of 5.25% is 54% below its 5-year average of 11.34%, near the low end of its 5-year range (3.83%–16.60%).
- What is the TTM average return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The TTM average return on equity (ROE) for TECH stock is 5.98%.
- What is the 3Y average return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The 3Y average return on equity (ROE) for TECH stock is 10.62%.
- What is the 5Y average return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The 5Y average return on equity (ROE) for TECH stock is 11.34%.
- What is the 10Y average return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The 10Y average return on equity (ROE) for TECH stock is 10.97%.
- What is the 15Y average return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The 15Y average return on equity (ROE) for TECH stock is 12.97%.
- What is the 20Y average return on equity (ROE) for Bio-Techne Corporation (TECH)?
- The 20Y average return on equity (ROE) for TECH stock is 15.12%.
TECH Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-06-30 | 3.83% |
| 2024-06-30 | 8.13% |
| 2023-06-30 | 14.51% |
| 2022-06-30 | 15.99% |
| 2021-06-30 | 8.98% |
| 2020-06-30 | 16.60% |
| 2019-06-30 | 8.24% |
| 2018-06-30 | 11.62% |
| 2017-06-30 | 8.13% |
| 2016-06-30 | 11.88% |
| 2015-06-30 | 12.72% |
| 2014-06-30 | 13.95% |
| 2013-06-30 | 15.26% |
| 2012-06-30 | 16.66% |
| 2011-06-30 | 19.16% |
| 2010-06-30 | 21.88% |
| 2009-06-30 | 23.06% |
| 2008-06-30 | 21.26% |
| 2007-06-30 | 19.45% |
| 2006-06-30 | 21.55% |
| 2005-06-30 | 24.69% |
| 2004-06-30 | 17.80% |
| 2003-06-30 | 19.19% |
| 2002-06-30 | 13.14% |
| 2001-06-30 | 19.16% |
| 2000-06-30 | 18.83% |
| 1999-06-30 | 17.25% |
| 1998-06-30 | 23.82% |
| 1997-06-30 | 22.66% |
| 1996-06-30 | 22.11% |
Related Metrics
About Bio-Techne Corporation
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kim Kelderman